Pharmaceutical excipients market seen doubling by 2035 on biologics and manufacturing shift

Market Research Future projects the global pharmaceutical excipients market will grow from $11.47 billion in 2025 to $24.88 billion by 2035, driven by biosimilars, biologics and continuous manufacturing. Europe leads today, while Asia-Pacific is expected to expand fastest as regulators tighten quality, impurity and supply-chain requirements.

Why it matters: - Pharmaceutical excipients are moving from commodity inputs to critical performance materials as drug makers prioritize stability, purity and release control. - The shift affects biologics, biosimilars, oral peptides, inhaled therapies and injectables, where formulation failure can delay approvals or trigger reformulation. - The market’s growth signals higher demand for documented, higher-specification suppliers rather than low-cost bulk materials.

What happened: - Market Research Future projected the global pharmaceutical excipients market will rise from $11.47 billion in 2025 to $24.88 billion by 2035. - The forecast implies an 8.1% CAGR over 2026-2035. - The first forecast year, 2026, is valued at $12.34 billion. - Europe held the largest regional share in 2025 at 34.6% of revenue. - Asia-Pacific is expected to grow the fastest at 9.9% CAGR through 2035. - The report also lists a free sample and customization option through the company’s sample request page and customization page.

The details: - Biosimilar and biologics pipeline expansion is a major driver. - Regulators are closely reviewing formulation risk tied to polysorbate 80, poloxamer 188, sucrose and arginine hydrochloride. - About $62 billion in original revenue is set to lose exclusivity between 2026 and 2030. - The FDA and EMA were reviewing 118 biosimilar applications as of late 2025. - Continuous manufacturing is increasing demand for excipients with tighter performance specs. - Twin-screw wet granulation running at 25 kg/hour can turn small changes in flow index or particle size into rejected product. - The FDA has authorized more than 20 continuous manufacturing applications. - Suppliers of immediately compressible co-processed blends with defined tabletability profiles are charging 18%-30% price premiums over commodity equivalents. - India’s Production Linked Incentive scheme for bulk drugs is funded at roughly $2.0 billion. - The U.S. FDA’s Quality Management Maturity program is pushing formulators toward suppliers with documented lot-to-lot consistency. - BASF, Roquette and DFE Pharma have collectively committed more than $900 million since 2023 to co-processing and lipid-based capacity. - Organic chemicals led product type in 2025 with a 69.7% share. - Fillers and diluents were the largest functional segment in 2025 with a 29.9% share. - Oral solid dosage forms were the largest formulation segment at $5.14 billion in 2025. - Parenteral formulations were the fastest-expanding formulation pool at $1.94 billion in 2025. - Plant-based excipients were the fastest-growing source segment at 8.9% CAGR. - Synthetic or chemical sources were projected to grow at 7.9% CAGR. - Mineral-based sources were projected to grow at 7.2% CAGR. - Animal-based sources were projected to grow at 5.4% CAGR.

Between the lines: - The report points to a market where compliance and documentation now carry as much weight as chemistry. - Supplier qualification is becoming harder as buyers focus on impurity limits, nitrosamine review and Certificates of Suitability coverage. - EDQM issued 340 new Certificates of Suitability across 2023-2025, reinforcing the advantage of already-documented suppliers. - Europe’s lead reflects its dense biologics manufacturing base and EDQM certification depth. - Asia-Pacific’s growth reflects regional manufacturing expansion, local supply-chain buildout and rising biosimilar output. - Competition is not centered on price alone; technical service and supply continuity are becoming key differentiators. - The top five suppliers hold an estimated 34%-41% of global revenue, showing a moderately concentrated market.

What’s next: - Demand should keep rising as more biosimilars and biologics move through development and commercialization. - Oral peptide programs are creating new opportunities for permeability enhancers such as sodium caprate and SNAC. - Nucleic-acid drugs are increasing demand for PEG-lipids, helper phospholipids and ionizable lipids. - Emerging-market localization efforts in India, Africa and parts of the Middle East are expected to expand regional excipient production. - Digital formulation services and predictive modeling are likely to become a margin layer on top of physical materials. - By 2035, the market is expected to reflect a broader shift toward documentation-rich, function-specific excipients.